Panag Pharma announces patent granted on novel formulation for treatment of ocular pain and inflammation
Halifax, Nova Scotia. Panag Pharma Inc., announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/722,991 Entitled: COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN, a patent which protects its novel topical ocular product formulations.
Panag Pharma’s ocular formulation leverages a novel drug platform targeting the endocannabinoid system, a key modulator of pain and inflammation in the eye. Panag Pharma’s topical ocular formulation is the first technology of its kind that is directed at ocular inflammation and pain. Panag Pharma continues an aggressive preclinical research program with Phase 1 clinical trials planned for the fourth quarter of 2017.
About Panag Pharma Inc.
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds. Learn more…